BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34557157)

  • 1. Translational Physiology of Anti-Müllerian Hormone: Clinical Applications in Female Fertility Preservation and Cancer Treatment.
    Rodgers RJ; Abbott JA; Walters KA; Ledger WL
    Front Endocrinol (Lausanne); 2021; 12():689532. PubMed ID: 34557157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMH prevents primordial ovarian follicle loss and fertility alteration in cyclophosphamide-treated mice.
    Sonigo C; Beau I; Grynberg M; Binart N
    FASEB J; 2019 Jan; 33(1):1278-1287. PubMed ID: 30113879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects.
    Roness H; Spector I; Leichtmann-Bardoogo Y; Savino AM; Dereh-Haim S; Meirow D
    J Assist Reprod Genet; 2019 Sep; 36(9):1793-1803. PubMed ID: 31250176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual suppression of follicle activation pathways completely prevents the cyclophosphamide-induced loss of ovarian reserve.
    Kashi O; Roness H; Spector I; Derech-Haim S; Meirow D
    Hum Reprod; 2023 Jun; 38(6):1086-1098. PubMed ID: 37015102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum anti-Müllerian hormone concentration and follicle density throughout reproductive life and in different diseases-implications in fertility preservation.
    Liebenthron J; Reinsberg J; van der Ven K; Saenger N; Kruessel JS; von Wolff M
    Hum Reprod; 2019 Dec; 34(12):2513-2522. PubMed ID: 31782794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
    Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
    Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The physiology and clinical utility of anti-Mullerian hormone in women.
    Dewailly D; Andersen CY; Balen A; Broekmans F; Dilaver N; Fanchin R; Griesinger G; Kelsey TW; La Marca A; Lambalk C; Mason H; Nelson SM; Visser JA; Wallace WH; Anderson RA
    Hum Reprod Update; 2014; 20(3):370-85. PubMed ID: 24430863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review.
    Iwase A; Nakamura T; Nakahara T; Goto M; Kikkawa F
    Reprod Sci; 2015 May; 22(5):519-26. PubMed ID: 25228631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian damage from chemotherapy and current approaches to its protection.
    Spears N; Lopes F; Stefansdottir A; Rossi V; De Felici M; Anderson RA; Klinger FG
    Hum Reprod Update; 2019 Nov; 25(6):673-693. PubMed ID: 31600388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A putative role for anti-Müllerian hormone (AMH) in optimising ovarian reserve expenditure.
    Pankhurst MW
    J Endocrinol; 2017 Apr; 233(1):R1-R13. PubMed ID: 28130407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation.
    Sermondade N; Sonigo C; Sifer C; Valtat S; Ziol M; Eustache F; Grynberg M
    Fertil Steril; 2019 Feb; 111(2):357-362. PubMed ID: 30527837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
    Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
    Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications.
    Broer SL; Broekmans FJ; Laven JS; Fauser BC
    Hum Reprod Update; 2014; 20(5):688-701. PubMed ID: 24821925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
    Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F
    Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].
    Gris-Martínez JM; Trillo-Urrutia L; Gómez-Cabeza JJ; Encabo-Duró G
    Med Clin (Barc); 2016 Feb; 146(3):97-103. PubMed ID: 26194532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What's new in 2014 about anti-Müllerian hormone?].
    Seroka-Vanhove A; Sonigo C; Roche C; Grynberg M
    J Gynecol Obstet Biol Reprod (Paris); 2014 Oct; 43(8):559-71. PubMed ID: 25042625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility.
    Hvidman HW; Bentzen JG; Thuesen LL; Lauritsen MP; Forman JL; Loft A; Pinborg A; Nyboe Andersen A
    Hum Reprod; 2016 May; 31(5):1034-45. PubMed ID: 26965431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure.
    Pascuali N; Scotti L; Di Pietro M; Oubiña G; Bas D; May M; Gómez Muñoz A; Cuasnicú PS; Cohen DJ; Tesone M; Abramovich D; Parborell F
    Hum Reprod; 2018 May; 33(5):844-859. PubMed ID: 29534229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated ovarian reserve depletion in female anti-Müllerian hormone knockout mice has no effect on lifetime fertility†.
    Guo R; Pankhurst MW
    Biol Reprod; 2020 Apr; 102(4):915-922. PubMed ID: 31837140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Female adolescents and young women previously treated for pediatric malignancies: assessment of ovarian reserve and gonadotoxicity risk stratification for early identification of patients at increased infertility risk.
    Parissone F; Di Paola R; Balter R; Garzon S; Zaffagnini S; Neri M; Vitale V; Tridello G; Cesaro S
    J Pediatr Endocrinol Metab; 2021 Jan; 34(1):25-33. PubMed ID: 33068384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.